After BRCA1 and BRCA2, FANCJ is the third most common ovarian cancer susceptibility gene: nearly 0.9– 2.5% of all ovarian cancer patients carry a splice-site, stop, or frameshift mutation in the FANCJ gene (Ramus et al, 2015; Norquist et al, 2016). The gene discussed is BRCA2; the disease is ovarian carcinoma.